The impact of rosiglitazone on regression of atherosclerosis: a serial 18F-fluorodeoxyglucose positron emission tomography [PET] study
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 05 Jan 2009 Biomarkers information updated
- 02 Jan 2009 Status changed from recruiting to suspended.
- 12 Jan 2006 New trial record.